- Home
- LXRX vs CHRS Comparison
LXRX vs CHRS Comparison
Compare LXRX & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- CHRS
- Stock Information
- Founded
- LXRX 1995
- CHRS 2010
- Country
- LXRX United States
- CHRS United States
- Employees
- LXRX N/A
- CHRS N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LXRX Health Care
- CHRS Health Care
- Exchange
- LXRX Nasdaq
- CHRS Nasdaq
- Market Cap
- LXRX 124.4M
- CHRS 112.5M
- IPO Year
- LXRX 2000
- CHRS 2014
- Fundamental
- Price
- LXRX $0.70
- CHRS $0.97
- Analyst Decision
- LXRX Buy
- CHRS Strong Buy
- Analyst Count
- LXRX 4
- CHRS 4
- Target Price
- LXRX $3.67
- CHRS $5.26
- AVG Volume (30 Days)
- LXRX 5.7M
- CHRS 1.7M
- Earning Date
- LXRX 05-13-2025
- CHRS 05-12-2025
- Dividend Yield
- LXRX N/A
- CHRS N/A
- EPS Growth
- LXRX N/A
- CHRS N/A
- EPS
- LXRX N/A
- CHRS 0.25
- Revenue
- LXRX $31,081,000.00
- CHRS $266,959,999.00
- Revenue This Year
- LXRX N/A
- CHRS N/A
- Revenue Next Year
- LXRX $84.78
- CHRS $9.02
- P/E Ratio
- LXRX N/A
- CHRS $3.89
- Revenue Growth
- LXRX 2481.48
- CHRS 3.78
- 52 Week Low
- LXRX $0.28
- CHRS $0.66
- 52 Week High
- LXRX $2.45
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- LXRX 60.07
- CHRS 48.50
- Support Level
- LXRX $0.63
- CHRS $0.92
- Resistance Level
- LXRX $0.71
- CHRS $1.12
- Average True Range (ATR)
- LXRX 0.07
- CHRS 0.07
- MACD
- LXRX -0.00
- CHRS -0.01
- Stochastic Oscillator
- LXRX 55.00
- CHRS 21.28
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.